✉ Email this page to a colleague
« Back to Dashboard
Solabegron is an investigational drug.
There have been 8 clinical trials for Solabegron. The most recent clinical trial was a Phase 2 trial, which was initiated on July 9th 2018.
The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].
Recent Clinical Trials for Solabegron
|A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)||Velicept Therapeutics, Inc.||Phase 2|
|Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women||Velicept Therapeutics, Inc.||Phase 2|
|Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects||Velicept Therapeutics, Inc.||Phase 1|